Neffy (epinephrine nasal spray) 1mg is approved for the emergency treatment of type 1 allergic reactions in children aged 4 ...

The FDA has approved neffy 1 mg epinephrine nasal spray for treating anaphylaxis and other type 1 allergic reactions in ...

Parents and pediatricians just gained one more tool to combat severe allergic reactions in young kids. San Diego-based ARS ...

The approval of neffy marks the first major advancement in epinephrine delivery for patients over four years of age in more ...

Neffy 1 mg is the “first significant innovation” for epinephrine delivery in small children aged 4 years and up in over 35 ...

Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 ...

The approval is supported by data from clinical trials, including pharmacodynamic and pharmacokinetic responses in adults and ...

The FDA has approved Neffy, a needle-free nasal spray, for children aged 4 and up, providing fast and effective treatment for severe allergic reactions and anaphylaxis.

US FDA approves ARS Pharma’s neffy 1 mg to treat type I allergic reactions for paediatric patients weighing 15 to less than 30 kilograms: San Diego Friday, March 7, 2025, 09:00 ...

The approval represents the first significant innovation in the delivery of epinephrine for this patient population in more than 35 years. Approval of neffy 1 mg follows FDA approval for neffy ...

For patients weighing 15kg to less than 30kg, the recommended dose is 1 spray of neffy 1mg. The Food and Drug Administration (FDA) has approved neffy ® (epinephrine nasal spray) 1mg for the ...

The US Food and Drug Administration (FDA) has approved ARS Pharmaceuticals' neffy 1mg (epinephrine nasal spray) for treating type one allergic reactions including anaphylaxis in paediatric ...